Spots Global Cancer Trial Database for doxil
Every month we try and update this database with for doxil cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | NCT00923936 | Sarcoma, Kaposi | Liposomal Doxor... Bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Combination Therapy for Recurrent Ovarian Cancer | NCT05610735 | Recurrent Ovari... | DOXIL Withaferin A Ashwagandha Combination of ... | 18 Years - | University of Louisville | |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT05748834 | Breast Cancer | Tucatinib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | NCT00923936 | Sarcoma, Kaposi | Liposomal Doxor... Bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Combination Therapy for Recurrent Ovarian Cancer | NCT05610735 | Recurrent Ovari... | DOXIL Withaferin A Ashwagandha Combination of ... | 18 Years - | University of Louisville | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | NCT01736943 | Acute Myelogeno... | Bortezomib Doxil | 18 Years - 80 Years | University of California, Davis | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer | NCT00456989 | Prostate Cancer | Taxotere Doxil | 18 Years - | University of Louisville | |
| Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | NCT01035658 | Ovarian Cancer Fallopian Tube ... Peritoneal Carc... | Pazopanib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer | NCT00456989 | Prostate Cancer | Taxotere Doxil | 18 Years - | University of Louisville | |
| Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer | NCT00316875 | Breast Cancer | lapatinib ditos... Doxil | 18 Years - | Northwestern University | |
| Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma | NCT00630409 | Metastatic Rena... | Gemcitabine Doxil | 18 Years - | University of Pittsburgh | |
| Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) | NCT00307294 | Prostate Cancer | Thalidomide Doxil | 18 Years - | University of Pittsburgh | |
| A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer | NCT00091442 | Breast Cancer | Docetaxel DOXIL | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | NCT00706953 | Multiple Myelom... | bortezomib; peg... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma | NCT00724568 | Multiple Myelom... | Lenalidomide Bortezomib Dexamethasone Doxil | 18 Years - | University of Michigan Rogel Cancer Center | |
| Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer | NCT00846612 | Ovarian Cancer | Doxil Bevacizumab (Av... | 18 Years - | NYU Langone Health | |
| A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma | NCT00516191 | Multiple Myelom... | Liposomal Doxor... | 18 Years - | University of California, San Francisco | |
| Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma | NCT00653328 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | atrasentan hydr... doxil | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) | NCT01227941 | Ovarian Cancer | MK-4827 + pegyl... MK-4827 + pegyl... | 18 Years - | Tesaro, Inc. | |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | NCT02489903 | Small Cell Carc... Carcinoma, Non-... Neuroendocrine ... Ovarian Epithel... | RRx-001 Cisplatin Etoposide Carboplatin Irinotecan Vinorelbine Doxil Gemcitabine Taxane Paclitaxel Nab-Paclitaxel Pemetrexed | 18 Years - | EpicentRx, Inc. | |
| Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement | NCT00507962 | Advanced Cancer | Cisplatin Liposomal Doxor... | - | M.D. Anderson Cancer Center | |
| CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | NCT00653952 | Ovarian Neoplas... | CAELYX Paclitaxel HCl | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | NCT00176293 | Prostate Cancer | dexamethasone doxorubicin | 18 Years - | University of Kentucky | |
| Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) | NCT00945139 | Ovarian Cancer | Doxil Avastin | 18 Years - | New Mexico Cancer Care Alliance | |
| Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | NCT01541332 | Multiple Myelom... | Pomalidomide Pegylated Lipos... Dexamethasone | 18 Years - | Oncotherapeutics | |
| Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy | NCT00216645 | Ovarian Neoplas... | doxorubicin hyd... | 20 Years - 79 Years | Janssen Pharmaceutical K.K. | |
| Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) | NCT00945139 | Ovarian Cancer | Doxil Avastin | 18 Years - | New Mexico Cancer Care Alliance | |
| Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT00344422 | Multiple Myelom... Myeloma M-Protein Myeloma Protein... | Vincristine, DO... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | NCT01202890 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... | Lenalidomide, L... Revlimid, Doxil... | - | New Mexico Cancer Care Alliance | |
| Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma | NCT04055753 | Soft Tissue Sar... | Doxil Doxorubicin | 18 Years - | Fox Chase Cancer Center | |
| MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) | NCT01227941 | Ovarian Cancer | MK-4827 + pegyl... MK-4827 + pegyl... | 18 Years - | Tesaro, Inc. | |
| Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement | NCT00507962 | Advanced Cancer | Cisplatin Liposomal Doxor... | - | M.D. Anderson Cancer Center | |
| Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer | NCT00316875 | Breast Cancer | lapatinib ditos... Doxil | 18 Years - | Northwestern University | |
| A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers | NCT00698451 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | doxorubicin HCL... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| DOXIL for Consolidation Therapy in Ovarian Cancer. | NCT00248248 | Ovarian Neoplas... | liposomal doxor... | 18 Years - | Southeastern Gynecologic Oncology | |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT05748834 | Breast Cancer | Tucatinib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer | NCT00316875 | Breast Cancer | lapatinib ditos... Doxil | 18 Years - | Northwestern University | |
| Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) | NCT00945139 | Ovarian Cancer | Doxil Avastin | 18 Years - | New Mexico Cancer Care Alliance | |
| Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | NCT01035658 | Ovarian Cancer Fallopian Tube ... Peritoneal Carc... | Pazopanib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma | NCT00116961 | Multiple Myelom... | Velcade Doxil Dexamethasone | 18 Years - | University of Michigan Rogel Cancer Center | |
| An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer | NCT00113607 | Ovarian Cancer | Trabectedin DOXIL Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | NCT01736943 | Acute Myelogeno... | Bortezomib Doxil | 18 Years - 80 Years | University of California, Davis | |
| Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT00344422 | Multiple Myelom... Myeloma M-Protein Myeloma Protein... | Vincristine, DO... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer | NCT00091442 | Breast Cancer | Docetaxel DOXIL | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | NCT01202890 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... | Lenalidomide, L... Revlimid, Doxil... | - | New Mexico Cancer Care Alliance | |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life | NCT00222105 | Multiple Myelom... | Doxil Thalidomide Dexamethasone | 18 Years - 75 Years | University of Kansas Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
